The U.S. Food and Drug Administration has recommended that COVID vaccine manufacturers update their formulas for fall doses, in an attempt to target the KP.2 strain of the JN.1 variant. The Thursday announcement came just a week after the agency’s Vaccines and Related Biological Products Advisory Committee voted to recommend a 'monovalent JN.1-lineage vaccine' at its June 5 meeting. As of the end of March 2024, the KP.2 variant was responsible for just 4% of infections in the U.S.
It makes sense to target the KP.2 strain because it is becoming the predominant strain — it is surging in California and will spread across the country,' Siegel told Fox News Digital. The KP.2 strain is 'highly immunoevasive,' the doctor warned — which means that immunity from previous variants and subvariants don't offer much protection.
On the other hand, the vaccine will cause a production of immune cells and antibodies that will continue to protect you against previous variants and subvariants,' Siegel added. It is especially important for high-risk groups, those who have chronic illnesses, the elderly and anyone who comes in contact with them, according to the doctor.
In a statement to Fox News Digital, vaccine maker Novavax — which makes protein-based vaccines — said the company 'just filed' its application for a JN.1 COVID vaccine. 'Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3,' the company said in a press release. 'The submission is in line with guidance from the U.S. FDA, European Medicines Agency and the World Health Organization to target the JN.